Long-term survival in an advanced gastric cancer patient treated with cetuximab in association with FOLFIRI: A case report

Daniela Adua, Francesca Di Fabio, Fabiola Lorena Rojas Llimpe, Sara Pini, Carmine Pinto

Research output: Contribution to journalArticle


In December 2004, a 52-year-old woman with metastatic gastric cancer was enrolled in the phase II clinical trial FOLCETUX, receiving cetuximab at an initial dose of 400 mg/m2 i.v. followed by weekly doses of 250 mg/m2, irinotecan 180 mg/m2 i.v. on day 1, LFA 100 mg/m2 i.v. followed by 5-FU 400 mg/m2 i.v. bolus and 600 mg/m2 i.v. 22-h continuous infusion on days 1 and 2 every two weeks, to a total of 17 cycles. CT and PET-CT performed after six weeks treatment failed to show any residual disease, with complete radiological response in accord to RECIST criteria and complete metabolic response. A total of 24 maintenance administrations with cetuximab alone (250 mg/m2 weekly) were performed, as foreseen by the protocol in responders. In November 2012 a clinical, radiological (CT) and metabolic (PET-CT) patient examination proved negative for recurrent disease, signifying 95 months' progression free survival.

Original languageEnglish
JournalJournal of Gastrointestinal Oncology
Issue number1
Publication statusPublished - 2014



  • Cetuximab
  • Gastric cancer

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology

Cite this